This morning regenerative medicine business Mesoblast Limited (ASX: MSB) reported a net loss before income tax benefits of US$90.2 million (A$113 million) for the financial year ending June 30, 2017. The biotech posted revenues for the year of US$2.4 million and after recently raising US$40 million now has cash on hand of US$84 million.
While the huge losses look bad the company is still valued at more than $600 million thanks to what some consider to be its large potential to generate commercial sales for its regenerative medicine stem cell therapy treatments for the likes of back pain, rheumatoid arthritis, or chronic heart failure.
The company has multiple clinical trials at various stages of progress all of which are aimed at proving the efficacy of its stem cell therapies in treating these common human ailments with new medical technologies.
However, these trials are costly with the company boasting much more promise than delivery over its life as a publicly traded business so far. Given its large losses investors might want to watch this business from the afar. Today shares change hands for $1.42 and are down 77% over the past five years.
